How big is the Latin America Glucagon-like Peptide-1 Agonists Market?

The Latin America Glucagon-like Peptide-1 Agonists Market size is expected to reach USD 203.89 million in 2024 and grow at a CAGR of 5.5% to reach USD 266.48 million by 2029. Read More

What is the current Latin America Glucagon-like Peptide-1 Agonists Market size?

In 2024, the Latin America Glucagon-like Peptide-1 Agonists Market size is expected to reach USD 203.89 million. Read More

Who are the key players in Latin America Glucagon-like Peptide-1 Agonists Market?

AstraZeneca, Biocon, Novo Nordisk A/S, Eli Lilly and Company and Sanofi Aventis are the major companies operating in the Latin America Glucagon-like Peptide-1 Agonists Market. Read More

What years does this Latin America Glucagon-like Peptide-1 Agonists Market cover, and what was the market size in 2023?

In 2023, the Latin America Glucagon-like Peptide-1 Agonists Market size was estimated at USD 192.68 million. The report covers the Latin America Glucagon-like Peptide-1 Agonists Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Latin America Glucagon-like Peptide-1 Agonists Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029. Read More

Latin America Glucagon-like Peptide-1 (GLP-1) AgonistsCompanies

This report lists the top Latin America Glucagon-like Peptide-1 (GLP-1) Agonists companies based on the 2023 & 2024 market share reports. Mordor Intelligence expert advisors conducted extensive research and identified these brands to be the leaders in the Latin America Glucagon-like Peptide-1 (GLP-1) Agonists industry.